Abstract
The migration of tumor cells is a prerequisite for tumor cell invasion and metastasis development, which accounts for over 90% of cancer mortality. Therefore a major focus of current tumor biological research is the study of those factors that regulate tumor cell migration. Those chemokines and neurotransmitters that bind to G-protein coupled receptors (also known as serpentine receptors) are the most prominent of these factors. Neurotransmitters have been identified that have not only a stimulatory (e.g. norepinephrine) effect, but an inhibitory effect (e.g. GABA) as well. This is an especially fortuitous development, because many known agonists and antagonists of neurotransmitter receptors are currently being successfully used in the treatment of other pathological conditions (e.g. β-blockers in the treatment of cardiovascular diseases). Likewise, chemokine receptor antagonists, which are under development for the treatment of HIV or rheumatoid arthritis, may be effective tools for the inhibition of chemokine-driven tumor cell migration as well. A further approach to inhibit tumor cell migration arises from the investigation of the relevant signal transduction pathways. The PKC alpha, for example, is a key enzyme in the regulation of tumor cell migration, but not of leukocyte migration. It thus offers a selective target opportunity for specific pharmacological agents to interfere with tumor cell migration. In this review we therefore summarize the current findings on those serpentine receptors involved in the neurotransmitter- and chemokine-regulated tumor cell migration, on the underlying signal transduction pathways, and on the opportunities to inhibit tumor cell migration and ultimately metastasis development with pharmaceutical agents.
Keywords: tumor cell, migration, metastasis, chemokines, neurotransmitters, serpentine receptors, signal transduction
Current Pharmaceutical Design
Title: Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Volume: 11 Issue: 3
Author(s): Frank Entschladen, Theodore L. Drell IV, Kerstin Lang, Jan Joseph and Kurt S. Zaenker
Affiliation:
Keywords: tumor cell, migration, metastasis, chemokines, neurotransmitters, serpentine receptors, signal transduction
Abstract: The migration of tumor cells is a prerequisite for tumor cell invasion and metastasis development, which accounts for over 90% of cancer mortality. Therefore a major focus of current tumor biological research is the study of those factors that regulate tumor cell migration. Those chemokines and neurotransmitters that bind to G-protein coupled receptors (also known as serpentine receptors) are the most prominent of these factors. Neurotransmitters have been identified that have not only a stimulatory (e.g. norepinephrine) effect, but an inhibitory effect (e.g. GABA) as well. This is an especially fortuitous development, because many known agonists and antagonists of neurotransmitter receptors are currently being successfully used in the treatment of other pathological conditions (e.g. β-blockers in the treatment of cardiovascular diseases). Likewise, chemokine receptor antagonists, which are under development for the treatment of HIV or rheumatoid arthritis, may be effective tools for the inhibition of chemokine-driven tumor cell migration as well. A further approach to inhibit tumor cell migration arises from the investigation of the relevant signal transduction pathways. The PKC alpha, for example, is a key enzyme in the regulation of tumor cell migration, but not of leukocyte migration. It thus offers a selective target opportunity for specific pharmacological agents to interfere with tumor cell migration. In this review we therefore summarize the current findings on those serpentine receptors involved in the neurotransmitter- and chemokine-regulated tumor cell migration, on the underlying signal transduction pathways, and on the opportunities to inhibit tumor cell migration and ultimately metastasis development with pharmaceutical agents.
Export Options
About this article
Cite this article as:
Entschladen Frank, Drell IV L. Theodore, Lang Kerstin, Joseph Jan and Zaenker S. Kurt, Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development, Current Pharmaceutical Design 2005; 11 (3) . https://dx.doi.org/10.2174/1381612053382197
DOI https://dx.doi.org/10.2174/1381612053382197 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis in Childhood Idiopathic Nephrotic Syndrome: An Update of Patchwork
Current Pediatric Reviews Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Therapeutic Potential of 4-1BB (CD137) in Cancer
Current Cancer Drug Targets Novel MK2 Inhibitors by Fragment Screening
Combinatorial Chemistry & High Throughput Screening αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology
Current Topics in Medicinal Chemistry Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Current and Emerging Strategies in Osteoporosis Management
Current Pharmaceutical Design Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Biomaterial and Stem Cell Interactions: Histological Biocompatibility
Current Stem Cell Research & Therapy Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Targeting Signaling Pathways in Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Radioactive Drugs in Drug Development Research: Quality Assurance Issues
Mini-Reviews in Medicinal Chemistry Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases
Current Clinical Pharmacology Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Neutrophil Proteome: Lessons from Different Standpoints
Protein & Peptide Letters Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy